Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...

See which services passed our rigorous vetting process. Share on Pinterest Mounjaro (tirzepatide) is an injectable medication that’s approved for diabetes by the Food and Drug Administration (FDA).

Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

Recently, the FDA ruled that the shortage of the weight loss drug tirzepatide is resolved ... continue its market outperformance, making it a buy for growth investors. Don’t miss this second ...